Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behçet's disease: Case report and the review of literature

Mod Rheumatol Case Rep. 2022 Jun 24;6(2):273-277. doi: 10.1093/mrcr/rxac032.

Abstract

We had two cases of trisomy 8-positive myelodysplastic syndrome (MDS) with incomplete Behçet's disease (BD) in which the remissions of both diseases were maintained by allogeneic stem cell transplantation (allo-SCT). Among MDS with BD patients, sometimes it is difficult to control the symptoms of BD with standard therapies such as corticosteroids and tumor necrosis factor (TNF) inhibitors. Although there should be careful consideration regarding indications for transplantation, our two cases, in which refractory BD was completely controlled by allo-SCT, suggest that allo-SCT can be one of the treatment options for higher-risk MDS with BD patients.

Keywords: Behçet’s disease; Trisomy 8; myelodysplastic syndrome; stem cell transplantation.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Behcet Syndrome* / complications
  • Behcet Syndrome* / diagnosis
  • Behcet Syndrome* / therapy
  • Chromosomes, Human, Pair 8
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Myelodysplastic Syndromes* / complications
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / therapy
  • Trisomy

Supplementary concepts

  • Chromosome 8, trisomy